Cannabinerol and NSC-34 Transcriptomic Analysis: Is the Dose Who Makes Neuronal Differentiation?

Andrea Valeri, Luigi Chiricosta, Agnese Gugliandolo, Federica Pollastro, Stefano Salamone, Valeria Domenica Zingale, Serena Silvestro, Emanuela Mazzon

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

Cannabis sativa L. proved to be a source of several phytocompounds able to help patients facing different diseases. Moreover, these phytocompounds can help ameliorate general conditions and control certain unpleasant effects of diseases. Some cannabinoids, however, provided more benefits applicable to settings other than palliative care. Using the NSC-34 cell line, we evaluated the barely known phytocompound named cannabinerol (CBNR) at different doses, in order to understand its unique characteristics and the ones shared with other cannabinoids. The transcriptomic analysis suggests a possible ongoing neuronal differentiation, principally due to the activation of cannabinoid receptor 1 (CB1), to which the phosphorylation of serine–threonine protein kinase (Akt) followed, especially between 20 and 7.5 µM. The increase of Neurod1 and Map2 genes at 7.5 µM, accompanied by a decrease of Vim, as well as the increase of Syp at all the other doses, point toward the initiation of differentiation signals. Our preliminary results indicate CBNR as a promising candidate to be added to the list of cannabinoids with neuronal differentiation-enhancer properties. However, further studies are needed to confirm this initial insight.

Lingua originaleInglese
Numero di articolo7541
RivistaInternational Journal of Molecular Sciences
Volume23
Numero di pubblicazione14
DOI
Stato di pubblicazionePubblicato - 1 lug 2022

Fingerprint

Entra nei temi di ricerca di 'Cannabinerol and NSC-34 Transcriptomic Analysis: Is the Dose Who Makes Neuronal Differentiation?'. Insieme formano una fingerprint unica.

Cita questo